This Isn’t Sci-Fi, it’s Spider Silk!DENVER, Sept. 05, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and insights, reports that Kraig Biocraft Laboratories (OTCQB: KBLB)(“Kraig Labs” or “the Company”), the global leader in spider silk-based super fiber technologies, is moving rapidly toward commercialization and is closing in on its first commercial sale of recombinant spider silk. Spider silk has long been one of the most ...

DENVER, Sept. 05, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, confirms that VENU (NYSE American: VENU), a trailblazer in premium hospitality and live entertainment, officially broke ground on its $300 million Sunset Amphitheater on June 13, 2025, in McKinney, Texas. According to Founder, Chairman, and CEO J.W. Roth, the Sunset VENU will be “the most luxurious fully seated, multi-configuration, ...

GUANGZHOU, CHINA, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Youxin Technology Ltd (NASDAQ: YAAS) (the “Company”), a software as a service (“SaaS”) and platform as a service (“PaaS”) provider committed to helping retail enterprises digitally transform their businesses, today announced the pricing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $6.0 million, before deducting underwriting fees and other offering expenses payable by the Company. The off ...

Regulatory milestone adds to its existing Orphan Drug Designation, creating additional regulatory and financial advantages for the Company’s lead cancer immunotherapy program SOUTH SAN FRANSCISCO, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative cellular immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that the U.S. Food and Drug Admini ...

公司会议安排 - 公司将于2025年9月10日参加B Riley Securities第八届年度消费者与TMT会议 在纽约市索菲特酒店举行 首席运营官Elena Plesco和投资者关系高级副总裁Robert Phillips将全天与投资者进行一对一会议[2] - 公司将于2025年9月17-18日参加Sidoti小型股虚拟会议 首席执行官Jay Jackson将于2025年9月18日星期四东部时间下午1:45进行正式投资者演示 投资者关系董事总经理David Jackson和Robert Phillips将陪同参加一对一投资者会议[3] 公司业务概况 - 公司是专注于另类资产管理的领先金融服务公司 业务范围包括数据驱动财富解决方案、技术创新和机构服务 专注于长寿资产和个性化财务规划 利用专有数据分析和数十年行业经验为全球个人和机构提供优化财务结果的创新解决方案[5] 投资者资源 - Sidoti会议演示的网络直播回放将在公司投资者关系网站上提供[4] - 联系投资者关系可通过邮箱ir@abacusgmcom 或通过B Riley及Sidoti会议代表安排与管理层的一对一会谈[4][6]

CORNELIUS, N.C., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Alpha Modus, Corp., a subsidiary of Alpha Modus Holdings Inc. (NASDAQ: AMOD) (“Alpha Modus” or the “Company”), today announced that it has filed a patent infringement lawsuit against Creative Realities, Inc. (“CRI”) in the United States District Court for the Eastern District of Texas, Marshall Division. The complaint asserts infringement of five of Alpha Modus’s foundational patents: U.S. Patent Nos. 10,360,571; 10,853,825; 10,977,672; 11,042,890; and 11, ...

财务业绩表现 - 第三季度净亏损369万美元 较去年同期亏损960万美元收窄62% 每股亏损0.58美元[1] - 前三季度净亏损1208万美元 较去年同期亏损1517万美元收窄20% 每股亏损1.87美元[1] - 第三季度营收4581万美元 同比增长7% 其中有利汇率影响138万美元[2] - 前三季度营收1.33亿美元 同比微增0.2% 其中有利汇率影响116万美元[2] 区域销售分析 - 美洲地区第三季度销售1690万美元 同比增长10% 主要因车床和加工中心出货增加[3] - 欧洲地区第三季度销售2417万美元 同比基本持平 但包含5%有利汇率影响 德国和法国出货量下降[4] - 亚太地区第三季度销售474万美元 大幅增长48% 主要因Takumi品牌立式加工中心和五轴机床需求增长[5] - 按九个月累计 美洲增长3% 欧洲下降3% 亚太增长7%[3] 订单情况 - 第三季度新订单4100万美元 同比下降22% 包含122万美元有利汇率影响[6] - 前三季度订单1.25亿美元 同比下降15% 包含92万美元有利汇率影响[6] - 美洲订单下降12% 欧洲订单骤降28% 亚太订单下降24%[7] - 欧洲订单下降主要因德国、英国和法国市场需求疲软[8] 盈利能力指标 - 第三季度毛利率20% 较去年同期18%提升200基点 因欧洲机器销售占比提高和固定成本下降[10] - 前三季度毛利率保持19%[10] - 销售和管理费用占比从24%降至23% 反映 discretionary spending 减少和医疗保险成本下降[11][12] 现金流与资本结构 - 现金及等价物增至4449万美元 较期初3333万美元增长33%[14] - 营运资本1.77亿美元 较期初1.81亿美元略有下降[14] - 公司执行股票回购计划 第三季度回购200万美元 累计回购530万美元[15] 业务战略与展望 - 公司专注于平衡资本配置策略 保持强劲资产负债表和流动性[16] - 持续投资新兴技术研发 考虑恢复股息支付[16] - 产品组合包括三大CNC品牌 Hurco和Milltronics配备自主开发控制系统 Takumi采用第三方控制系统[16] - 终端市场涵盖航空航天、医疗设备、能源等行业[16]

公司动态 - Aptorum Group与DiamiR Biosciences将于2025年9月10日11时在纽约Lotte New York Palace酒店联合出席H.C. Wainwright第27届全球投资会议 [1][2] - 双方于2025年7月16日达成全股票合并协议，合并后DiamiR将成为Aptorum全资子公司，交易预计于2025年第四季度完成 [3] 业务聚焦 - Aptorum Group为临床阶段生物制药公司，专注于肿瘤学（含孤儿瘤适应症）及传染性疾病领域未满足医疗需求的治疗资产开发与商业化 [4] - DiamiR为私有分子诊断公司，通过CLIA认证及CAP认可实验室提供基于血浆中脑部富集及炎症相关microRNA特征的微创检测技术，拥有全球超50项专利授权，并提供蛋白质与遗传生物标志物分析服务 [5] 公司架构 - 合并交易需双方股东批准及符合惯例交割条件 [3] - Aptorum已提交6-K表格披露合并细节，并将向SEC提交S-4登记声明文件，向股东寄发股东大会通知 [9] 信息披露 - 股东可通过SEC官网（www.sec.gov）或联系Aptorum投资者关系部门（+44 20 80929299）获取股东大会通知及代理声明/招股书等文件 [9][12]

BOULDER, CO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- FST Corp. (Nasdaq: KBSX), a leading manufacturer and marketer of steel and graphite golf shafts and a provider of other golf-related services, today announced that it will participate in the 27th Annual H.C. Wainwright Global Investment Conference, taking place September 8th through September 10th, 2025. Sebastian Tadla, Chief Financial Officer, and Kathee Lin, Head of Investor Relations of FST Corp., will deliver a company presentation and be available for on ...

– 17 abstracts accepted, including one oral presentation – – Data from the REFRESH real-world study highlight efficacy of once-nightly sodium oxybate when switching from twice-nightly oxybates – – REFRESH study also highlights efficacy in those who were new to oxybate or returning to oxybate after discontinuing twice-nightly oxybate – DUBLIN, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today a ...